Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics
Periodontitis is a prevalent chronic inflammatory disease that exacerbates systemic inflammation and poses challenges for glycemic control in diabetic patients. While scaling and root planing (SRP) remains the cornerstone of periodontal therapy, adjunctive treatments such as Arestin (minocycline microspheres) have shown promise in enhancing clinical outcomes. This study aims to evaluate the impact of adding Arestin to SRP on periodontal pocket closure, glycemic control, and systemic inflammation in diabetic…
Conditions studied
Periodontitis, Diabetes Mellitus Type 2
About this study
Periodontitis is a prevalent chronic inflammatory disease that exacerbates systemic inflammation and poses challenges for glycemic control in diabetic patients. While scaling and root planing (SRP) remains the cornerstone of periodontal therapy, adjunctive treatments such as Arestin (minocycline microspheres) have shown promise in enhancing clinical outcomes. This study aims to evaluate the impact of adding Arestin to SRP on periodontal pocket closure, glycemic control, and systemic inflammation in diabetic patients with periodontitis.
Interventions
- Drug: local antibiotic application of topical minocycline — Scaling and Root planing + local application of Arestin ( Minocycline microsphere)
- Procedure: Scaling and Root Planing — Only scaling and root planing
Primary outcomes
- Pocket Closure (Baseline, 3 Months, 6 Months)
Eligibility information
Study locations
- Case Western Reserve University, Cleveland, Ohio 44106 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-18.